Skip to main navigation Skip to search Skip to main content

Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers to prevent end-stage kidney disease in patients who do not have diabetes

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Trial commentary on: Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117-124.
Original languageEnglish
Pages (from-to)450-451
Number of pages2
JournalMedical Journal of Australia
Volume181
Issue number8
Publication statusPublished - Oct 2004
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers to prevent end-stage kidney disease in patients who do not have diabetes'. Together they form a unique fingerprint.

Cite this